13D Filings
Syros Pharmaceuticals, Inc.
Amendment
Ownership

2.60%

Total Shares

707,114

Issuer CIK

1556263

CUSIP

87184Q206

Event Date

Nov 17, 2024

Accepted

Mar 27, 2025, 06:17 PM

Reporting Persons (3)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Samsara BioCapital, L.P.
Partnership
2.60%707,1140707,114
Samsara BioCapital GP, LLC
Other
2.60%707,1140707,114
Srinivas Akkaraju
Individual
2.60%707,1140707,114
Disclosure Items (3)

Security Title

Common Stock, $0.001 par value per share

Issuer Name

Syros Pharmaceuticals, Inc.

Issuer Address

35 CambridgePark Drive, 4th Floor, Cambridge, MA, 02140

Percentage of Class

Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D/A set forth the aggregate number of shares of common stock and percentages of the shares of common stock beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon 26,832,457 shares of the Issuer's common stock outstanding as of October 24, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on October 31, 2024. Samsara LP directly holds warrants exercisable for up to 707,114 shares of common stock. Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is a managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP.

Number of Shares

Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D/A set forth the number of shares of common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.

Transactions

Except as set forth below, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days. Weighted Low High Reporting No. Average Price Price Transaction Person Date Shares Price ($) ($) ($) Open Market Sale Samsara LP 11/18/2024 958,310 $0.21 $0.18 $0.26 Open Market Sale Samsara LP 11/19/2024 74,128 $0.21 $0.21 $0.21 Open Market Sale Samsara LP 11/20/2024 753,989 $0.26 $0.26 $0.27 Open Market Sale Dr. Akkaraju 12/30/2024 9,333 $0.25 $0.25 $0.25

Shareholders

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the securities beneficially owned by any of the Reporting Persons.

Date of 5% Ownership

The Reporting Persons ceased to be the beneficial owners of more than five percent of the common stock on November 20, 2024.

Exhibit 99.1 Joint Filing Agreement

Syros Pharmaceuticals, Inc. — Schedule 13D | 13D Filings